Nirsevimab Considerably Reduces Hospitalizations for respiratory Infections in Infants, New Study Finds
Table of Contents
A new meta-analysis published in JAMA Pediatrics suggests that nirsevimab (Beyfortus) offers ample protection against hospitalization and emergency department (ED) visits not only for respiratory syncytial virus (RSV) but also for other lower respiratory tract infections (LRTIs) in infants and young toddlers.
A team of researchers at York University in Toronto analyzed data from 11 real-world observational studies encompassing a total of 291,277 children – 263,755 who received nirsevimab and 27,522 serving as controls.The studies, which tracked patients throughout the entire RSV season, reported results between january and June 2025.
Broadening the Protective Scope of Nirsevimab
Approved in 2023, nirsevimab is a long-acting monoclonal antibody designed to provide passive immunity to infants up to six months old, and to high-risk infants in their second year of life, against RSV-related LRTIs. While previous research has focused on its efficacy against RSV specifically,this new analysis demonstrates a wider benefit. “Although several observational studies have examined these outcomes following nirsevimab management,no pooled analysis has yet evaluated the extended real-world effectiveness of nirsevimab for these broader end points,” the investigators wrote.
The meta-analysis revealed impressive results: nirsevimab was associated with a 62% reduction in all-cause LRTI hospitalizations (odds ratio [OR], 0.38), a 48% reduction in all-cause LRTI ED visits (OR, 0.52), and a remarkable 76% reduction in RSV-related ED visits (OR, 0.24). These findings, drawn from studies conducted in Spain, France, the United States, and Chile, indicate that the benefits of nirsevimab extend beyond RSV alone.
Impact on Overall Hospitalizations and Future Implications
While nirsevimab demonstrated significant protective effects against LRTI-specific hospitalizations and ED visits,no statistically significant difference was observed in all-cause hospitalizations between the nirsevimab and control groups (OR,0.56). Though, sensitivity analyses confirmed the robustness of the primary findings across multiple scenarios.
“These findings suggest that nirsevimab provides real-world protective benefits beyond those demonstrated or recognized for RSV-specific outcomes, further supporting its implementation in infant immunization programs to reduce the respiratory-related disease burden and health care utilization,” the researchers concluded. They further explained that the observed reduction in all-cause LRTIs, even those not caused by RSV, aligns with findings from both randomized clinical trials and real-world evidence.
The researchers posit that RSV is responsible for a substantial proportion – up to 80% in temperate regions – of medically attended respiratory illnesses during annual outbreaks. consequently,protecting against RSV naturally leads to a decrease in all-cause respiratory illness. “Consequently, estimates of nirsevimab effectiveness against all-cause respiratory outcomes, especially those derived from studies conducted during peak RSV circulation, are likely driven by its p
Why: The study aimed to evaluate the real-world effectiveness of nirsevimab beyond its known efficacy against RSV, specifically looking at its impact on all-cause lower respiratory tract infections (LRTIs). Researchers wanted to determine if the benefits extended to other respiratory illnesses.
Who: The study involved 291,277 children, divided into two groups: 263,755 who received nirsevimab and
